«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2025 06

Page:

1039-1043

Research Field:

Publishing date:

Info

Title:

Research progress on the role and mechanism of SETD5 in the formation of tumor stemness features

Author(s):

SUN Dianyu; LI Chenghao

Department of Gastroenterology,Yanbian University Hospital£¨Yanbian Hospital£©£¬Jilin Yanji 136200£¬China.

Keywords:

SETD5; cancer stemness; hypoxia; glycolysis; PI3K/AKT/mTOR pathway

PACS:

R73

DOI:

10.3969/j.issn.1672-4992.2025.06.022

Abstract:

SET domain-containing protein 5(SETD5),a member of the SET family of structural domain lysine methyltransferases(KMTs),is involved in the regulation of a wide range of cellular functions,including cell cycle regulation,command of brain and nervous system development,and maintenance of intra-tissue homeostasis.SETD5 also promotes tumour development by regulating gene expression and chromatin status.In recent years,SETD5 has been found to play a key role in the formation of tumour stemness characteristics,which is expected to become a new therapeutic target.In this paper,the structure and function of SETD5 are discussed in depth,and the relationship and regulatory mechanism between SETD5 and tumour stemness features are highlighted,aiming to provide new methods and ideas for the diagnosis and treatment of tumours,especially for inhibiting their stemness features.

References:

£Û1£ÝSESSA A,FAGNOCCHI L,MASTROTOTARO G,et al.SETD5 regulates chromatin methylation state and preserves global transcriptional fidelity during brain development and neuronal wiring£ÛJ£Ý.Neuron,2019,104(2):271-289.e13.
£Û2£ÝGREGORY K,JOHN S,ROBERT W.Deletion of 3p25.3 in a patient with intellectual disability and dysmorphic features with further definition of a critical region£ÛJ£Ý.American Journal of Medical Genetics(Part A£©,2013,161A(6):1405-1408.
£Û3£ÝLI MY,HOU YA,ZHANG ZW,et al.Structure,activity and function of the lysine methyltransferase SETD5#13£ÛJ£Ý.Frontiers in Endocrinology,2023,(14):1089527-1089527.
£Û4£ÝOSIPOVICH AB,GANGULA R,VIANNA PG,et al.Setd5 is essential for mammalian development and the co-transcriptional regulation of histone acetylation£ÛJ£Ý.Development(Cambridge,England),2016,143(24):4595-4607.
£Û5£ÝJIN P,TAN Y,ZHANG W,et al.Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia£ÛJ£Ý.Neoplasia,2020,22(9):447-457.
£Û6£ÝZAGHI M,LONGO F,MASSIMINO L,et al.SETD5 haploinsufficiency affects mitochondrial compartment in neural cells£ÛJ£Ý.Molecular Autism,2023,14(1):20.
£Û7£ÝMANOKARAN RK,OCHI A,KERR E,et al.Drug-resistant focal epilepsy in a girl with SETD5-related intellectual disability£ÛJ£Ý.Seizure:European Journal of Epilepsy,2023,(112):109-111.
£Û8£ÝLI MK,QIU C,BIAN YJ,et al.SETD5 modulates homeostasis of hematopoietic stem cells by mediating RNA Polymerase ¢ò pausing in cooperation with HCF-1£ÛJ£Ý.Leukemia,2021,36(4):1111-1122.
£Û9£ÝANDERSON E,LAM Z,ARUNDEL P,et al.Expanding the phenotype of SETD5-related disorder and presenting a novel association with bone fragility£ÛJ£Ý.Clinical genetics,2021,100(3):352-354.
£Û10£ÝCHEUNG MY,ROBERTS C,SCAMBLER P,et al.Setd5 is required in cardiopharyngeal mesoderm for heart development and its haploinsufficiency is associated with outflow tract defects in mouse£ÛJ£Ý.Genesis(New York:2000),2021,59(7-8):e23421.
£Û11£ÝDANGONI GD,TEIXEIRA ACB,DA COSTA SS,et al.Germline mutations in cancer predisposition genes among pediatric patients with cancer and congenital anomalies£ÛJ£Ý.Pediatric Research,2024,95£º1346-1355.
£Û12£ÝYU SE,KIM MS,PARK SH,et al.SET domain-containing protein 5 is required for expression of primordial germ cell specification-associated genes in murine embryonic stem cells£ÛJ£Ý.Cell Biochemistry and Function,2017,35(5):247-253.
£Û13£ÝRAO HY,LIU CW,WANG AT,et al.SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer£ÛJ£Ý.Nature Communications,2023,14(1):7572.
£Û14£ÝCHEN ZG,YAN CT,DOU YL,et al.The role of a newly identified SET domain-containing protein,SETD3,in oncogenesis£ÛJ£Ý.Haematologica,2013,98(5):739-743.
£Û15£ÝFARIA JA,CORREA NC,DE ANDRADE C,et al.SET domain-containing protein 4(SETD4) is a newly identified cytosolic and nuclear lysine methyltransferase involved in breast cancer cell proliferation£ÛJ£Ý.Journal of Cancer Science Therapy,2013,5(2):58-65.
£Û16£ÝO' NEILL DJ,WILLIAMSON SC,ALKHARAIF D,et al.SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells£ÛJ£Ý.Epigenetics,2014,9(7):942-950.
£Û17£ÝDING YY,ZHAO HJ,NIU WB,et al.M2 macrophage-derived extracellular vesicles containing microRNA-501-3p promote colon cancer progression through the SETD7/DNMT1/SOCS3 axis£ÛJ£Ý.Diseases of the Colon and Rectum,2023,66(12):e1234-e1245.
£Û18£ÝYU H,SUN J,ZHAO C,et al.SET domain containing protein 5(SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients£ÛJ£Ý.BMC Cancer,2019,19(1):1-10.
£Û19£ÝYANG ZT,ZHANG CY,CHE N,et al.SET domain-containing 5 facilitates tumor growth and pulmonary metastasis through up-regulation of AKT1 signaling in breast cancer£ÛJ£Ý.The American Journal of Pathology,2020,191(1):180-193.
£Û20£ÝPIAO L,LI H,FENG Y,et al.SET domain-containing 5 is a potential prognostic biomarker that promotes esophageal squamous cell carcinoma stemness£ÛJ£Ý.Experimental Cell Research,2020,389(1):111861.
£Û21£ÝWANG Z,HAUSMANN S,LYU R,et al.SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy£ÛJ£Ý.Cancer Cell,2020,37(6):834-849.e13.
£Û22£ÝPARK M,MOON B,KIM JH,et al.Downregulation of SETD5 suppresses the tumorigenicity of hepatocellular carcinoma cells£ÛJ£Ý.Molecules and cells,2022,45(8):550-563.
£Û23£ÝCHO HI,JO S,KIM MS,et al.SETD5 regulates the OGT-catalyzed O-GlcNAcylation of RNA polymerase II,which is involved in the stemness of colorectal cancer cells£ÛJ£Ý.Scientific Reports,2023,13(1):19885.
£Û24£ÝSHI J,YU LT,ZHU CH,et al.Knockdown of SETD5 inhibited glycolysis and tumor growth in gastric cancer cells by down-regulating Akt signaling pathway£ÛJ£Ý.Open Life Sciences,2023,18(1):20220697.
£Û25£ÝLO¦TC P,GAELLE V,FABRICE S,et al.miR126-5p repression of ALCAM and SetD5 in endothelial cells regulates leucocyte adhesion and transmigration£ÛJ£Ý.Cardiovascular Research,2014,102(3):436-447.
£Û26£ÝAMIRI-FARSANI M,TAHERI Z,TIRBAKHSH GOURAN S,et al.Cancer stem cells:Recent trends in cancer therapy£ÛJ£Ý.Nucleosides,Nucleotides Nucleic Acids,2024,2014£º31-32.
£Û27£ÝNAIRUZ T,MAHMUD Z,MANIK RK,et al.Cancer stem cells:An insight into the development of metastatic tumors and therapy resistance£ÛJ£Ý.Stem Cell Reviews and Reports,2023,19(6):1577-1595.
£Û28£ÝNIU QH,YE SS,ZHAO L,et al.The role of liver cancer stem cells in hepatocellular carcinoma metastasis£ÛJ£Ý.Cancer Biology Therapy,2024,25(1):2321768.
£Û29£ÝCHEN Q,SUN Z,LI JF,et al.SET domain-containing protein 5 enhances the cell stemness of non-small cell lung cancer via the PI3K/Akt/mTOR pathway£ÛJ£Ý.Journal of Environmental Pathology,Toxicology and Oncology,2021,40(2):55-63.
£Û30£ÝYANG ZT,ZHANG CY,LIU XZ,et al.SETD5 regulates glycolysis in breast cancer stem-like cells and fuels tumor growth£ÛJ£Ý.The American Journal of Pathology,2022,192(4):712-721.
£Û31£ÝRASHID M,ZADEH LR,BARADARAN B,et al.Up-down regulation of HIF-1¦Á in cancer progression£ÛJ£Ý.Gene,2021,798(prepublish):145796.
£Û32£ÝWICKS EE,SEMENZA GL.Hypoxia-inducible factors:Cancer progression and clinical translation£ÛJ£Ý.The Journal of Clinical Investigation,2022,132(11):e159839.
£Û33£ÝZHANG Q,HAN ZZ,ZHU YB,et al.Role of hypoxia inducible factor-1 in cancer stem cells(Review)£ÛJ£Ý.Molecular Medicine Reports,2020,23(1):17.
£Û34£ÝYAN F,TENG Y,LI XY,et al.Hypoxia promotes non-small cell lung cancer cell stemness,migration,and invasion via promoting glycolysis by lactylation of SOX9£ÛJ£Ý.Cancer Biology Therapy,2024,25(1):2304161.
£Û35£ÝCHELAKKOT C,CHELAKKOT VS,SHIN Y,et al.Modulating glycolysis to improve cancer therapy£ÛJ£Ý.International Journal of Molecular Sciences,2023,24(3):2606.
£Û36£ÝZHU X,CHEN HH,GAO CY,et al.Energy metabolism in cancer stem cells£ÛJ£Ý.World Journal of Stem Cells,2020,12(6):448-461.
£Û37£ÝQIAO Z,LI Y,LI SM,et al.Hypoxia-induced SHMT2 protein lactylation facilitates glycolysis and stemness of esophageal cancer cells£ÛJ£Ý.Molecular and Cellular Biochemistry,2024,479£º3063-3076.
£Û38£ÝWAN XY,MA DY,SONG GL,et al.The SOX2/PDIA6 axis mediates aerobic glycolysis to promote stemness in non-small cell lung cancer cells£ÛJ£Ý.Journal of Bioenergetics and Biomembranes,2024,56£º323-332.
£Û39£ÝDANDO I,CORDANI M,DALLA POZZA E,et al.Antioxidant mechanisms and ROS-related microRNAs in cancer stem cells£ÛJ£Ý.Oxidative Medicine and Cellular Longevity,2015,2015:425708.
£Û40£ÝKARAMI FATH M,EBRAHIMI M,NOURBAKHSH E,et al.PI3K/Akt/mTOR signaling pathway in cancer stem cells£ÛJ£Ý.Pathology-Research and Practice,2022,(237):154010.
£Û41£ÝLIANG CX,JIANG YJ,SUN LZ.Vitexin suppresses the proliferation,angiogenesis and stemness of endometrial cancer through the PI3K/AKT pathway£ÛJ£Ý.Pharmaceutical Biology,2023,61(1):581-589.
£Û42£ÝLI P,WANG WH,ZHU BW,et al.PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer£ÛJ£Ý.Environmental Toxicology,2024,39(5):2869-2880.
£Û43£ÝYANG Y,ZHANG T,WU L.TUFT1 facilitates metastasis,stemness,and vincristine resistance in colorectal cancer via activation of PI3K/AKT pathway£ÛJ£Ý.Biochemical Genetics,2021,59(4):1-15.
£Û44£ÝHALDER SK,RACHAKONDA G,DEANE NG,et al.Smad7 induces hepatic metastasis in colorectal cancer£ÛJ£Ý.British Journal of Cancer,2008,99(6):957-965.
£Û45£ÝXUE Y,LAI LH,LIAN WW,et al.SOX9/FXYD3/Src axis is critical for ER+ breast cancer stem cell function£ÛJ£Ý.Molecular Cancer Research,2019,17(1):238-249.
£Û46£ÝWANG WW,WANG YB,WANG DQ,et al.Integrin beta-8(ITGB8) silencing reverses gefitinib resistance of human hepatic cancer HepG2/G cell line£ÛJ£Ý.International Journal of Clinical and Experimental Medicine,2015,8(2):3063-3071.
£Û47£ÝTIAN W,LI JT,WANG Z,et al.HYD-PEP06 suppresses hepatocellular carcinoma metastasis,epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/¦Â-catenin signaling activation£ÛJ£Ý.Acta Pharmaceutica Sinica B,2021,11(6):1592-1606.
£Û48£ÝWANG RJ,LI S,HOU Q,et al.Propofol inhibits colon cancer cell stemness and epithelial-mesenchymal transition by regulating SIRT1,Wnt/¦Â-catenin and PI3K/AKT/mTOR signaling pathways£ÛJ£Ý.Discover Oncology,2023,14(1):137.

Memo

Memo:

¼ªÁÖÊ¡×ÔÈ»¿Æѧ»ù½ð£ÛÃæÉÏÏîÄ¿£¨Ò½Ñ§¿ÆѧÁìÓò£©£Ý£¨±àºÅ£ºYDZJ202301ZYTS203£©

Common functions

Last Update: 1900-01-01